MRNA Influenza Vaccine Reduces Infection Risk in Adults Over 50

Seasonal influenza remains a significant cause of morbidity and mortality in older adults, particularly as immunosenescence (the age-related decline in immune function) reduces the efficacy of traditional inactivated vaccines [1, 2]. Current egg-based manufacturing platforms often struggle with antigenic drift (minor genetic changes in the virus that lead to a mismatch between the vaccine and circulating strains), which can significantly lower seasonal effectiveness [3, 4]. To address these limitations, researchers have utilized lipid-nanoparticle delivery systems (microscopic fatty capsules that protect and transport genetic material into cells) to develop messenger RNA vaccines against influenza [5, 6]. Previous clinical data have evaluated whether these platforms elicit hemagglutination inhibition titers (a laboratory measure of the ability of antibodies to prevent the virus from entering cells) that are comparable to traditional egg-based comparators [7, 3]. Recent phase 3 trial data now offer direct clinical evidence regarding the efficacy and safety of these mRNA vaccines in older adults, providing physicians with new comparative metrics for seasonal immunization planning.